Skip to Content

LX1033 Approval Status

FDA Approved: No
Brand name: LX1033
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Irritable Bowel Syndrome

LX1033 is an oral tryptophan hydroxylase inhibitor in development for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

Development Status and FDA Approval Process for LX1033

DateArticle
Dec  3, 2013Lexicon Completes Phase 2 Study of LX1033 in IBS-D
Dec 17, 2012Lexicon's Drug Candidate For Irritable Bowel Syndrome (LX1033) Receives Fast Track Status From The FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide